(Schlenk & Dohner, ASH 2013)
STANDARD TREATMENT:
INDUCTION PHASE
+
CONSOLIDATION PHASE
Consists of: Cytarabine (AraC) + Anthracycline + bone marrow transplant (case dependent)
HDAC inhibitors
NEW THERAPEUTIC STRATEGIES:
Target Fusion Protein
MLL-AF9
AML1-ETO
MLL-methyltransferase
activity inhibition
(Cunningham, PNAS 2012; Cao, Mol Cell 2014)
AML1/CBFb
binding inhibition
Target cofactor interactions
MLL-AF9
AML1-ETO
(Grembecka, Nat. Chem. Biol. 2012; Dawson, Nature 2011; Daigle, Cancer
Cell 2011)
Inhibit corepressors
Inhibit DOT1L activity,
Menin1-MLL
interaction, etc.
